Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-06-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
第二届监事会第十一次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Shenzhen Microchip Biotechnology Co., Ltd. It details the approval of a convertible bond issuance plan, including terms such as issuance scale, interest rates, conversion price, redemption clauses, and issuance methods. The document also references regulatory approvals and shareholder authorizations related to the bond issuance. The content is focused on corporate governance decisions and financing plans rather than presenting financial statements or detailed financial performance data. The document length is 3345 characters, which is relatively short and consistent with an announcement rather than a full report. Given the detailed discussion of the bond issuance plan and related approvals, this fits best under Capital/Financing Update (CAP).
2022-06-30 Chinese
深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券证券募集说明书摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书摘要" which translates to "Prospectus Summary" or "Offering Circular Summary". It is issued by Shenzhen Microchip Biotechnology Co., Ltd. and relates to the issuance of convertible corporate bonds to unspecified investors. The content includes detailed information about the bond issuance, risks, credit ratings, subscription commitments by major shareholders and management, and the use of raised funds. It also contains financial and management analysis sections, typical of a detailed offering prospectus. This type of document is a capital raising disclosure related to financing activities, specifically a bond issuance. It is not an annual or interim report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. It is a detailed capital/financing update document describing the terms, risks, and commitments related to a convertible bond issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-06-30 Chinese
深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券信用评级报告
Capital/Financing Update Classification · 95% confidence The document is a detailed credit rating report issued by CSCI Pengyuan Credit Rating Co., Ltd. for Shenzhen Microchip Biotechnology Co., Ltd. regarding its issuance of convertible corporate bonds. It includes extensive financial data, company background, bond issuance details, project investment plans, and market environment analysis. The content focuses on credit rating, bond issuance, and financial evaluation rather than a general annual report or earnings release. It is not a regulatory announcement or a brief notice but a comprehensive credit rating report. This type of document fits best under the category of Capital/Financing Update (CAP), as it provides detailed information about the company's financing activity through bond issuance and credit rating assessment.
2022-06-30 Chinese
独立董事关于第二届董事会第十九次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 19th meeting of the second board of directors of Shenzhen Microcore Biotechnology Co., Ltd. The content focuses on approval and opinions regarding the issuance of convertible bonds, listing of these bonds, and the opening of a special account for raised funds. It references compliance with company law, securities law, and stock exchange listing rules. The document is a formal opinion related to board meeting resolutions and does not contain financial statements or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it a simple announcement of a report. It is also not a management change, earnings release, or legal proceeding. The document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory disclosure related to corporate governance and financing matters but does not fit other specific categories.
2022-06-30 Chinese
深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券证券募集说明书
Capital/Financing Update Classification · 95% confidence The document is titled '募集说明书' which translates to 'Offering Prospectus' or 'Offering Circular'. It is issued by Shenzhen Microchip Biotechnology Co., Ltd. and details the issuance of convertible corporate bonds to unspecified investors. The content includes detailed information about the bond issuance, credit ratings, risks, subscription commitments by shareholders and management, and regulatory compliance. This type of document is a detailed disclosure related to capital raising activities, specifically a bond issuance. It is not an annual or interim financial report, nor is it a simple announcement or presentation. It is a formal prospectus for a capital market transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-06-30 Chinese
向不特定对象发行可转换公司债券发行公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of convertible corporate bonds by Shenzhen Microchip Biotechnology Co., Ltd. It includes extensive information about the bond issuance process, terms, conditions, subscription details, credit ratings, and regulatory approvals. The text references regulatory bodies such as the China Securities Regulatory Commission and the Shanghai Stock Exchange, and it discusses the offering size, pricing, conversion terms, and underwriting arrangements. The document is not a financial report like an annual or interim report, nor is it a transcript, audit report, or management change announcement. It is a formal announcement of a capital raising activity through convertible bonds, including detailed issuance terms and subscription instructions. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not merely a brief announcement or a report publication notice but a substantive issuance announcement.
2022-06-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.